Abstract CT196: Therapeutic dose selection for belantamab mafodotin, a BCMA-targeting agent, in patients with relapsed/refractory multiple myeloma (RRMM): Application of population pharmacokinetics (PopPK) and exposure-response (E-R) analyses
Abstract
Background: Belantamab mafodotin (GSK2857916) is a first-in-class B-cell maturation antigen (BCMA)-targeting immunoconjugate with a humanized afucosylated anti-BCMA mAb conjugated to a cytotoxic payload mafodotin (MMAF) by a protease-resistant maleimidocaproyl linker (mc). This antibody-drug conjugate (ADC) binds to BCMA and eliminates MM cells by a multimodal mechanism. It delivers MMAF to MM cells which inhibits microtubule polymerization,...
Paper Details
Title
Abstract CT196: Therapeutic dose selection for belantamab mafodotin, a BCMA-targeting agent, in patients with relapsed/refractory multiple myeloma (RRMM): Application of population pharmacokinetics (PopPK) and exposure-response (E-R) analyses
Published Date
Aug 15, 2020
Journal
Volume
80
Issue
16_Supplement
Pages
CT196 - CT196
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History